ArticleDrug discovery today2020
Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders.
Article in Drug discovery today, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A study on the effect of COVID-19 infection on the serum concentration of antipsychotic drugs.BMC psychiatry · 2025Article
- Effect of psychotropics on the risk of COVID-19 in middle-aged and older adults.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2023Article
- Olanzapine, risperidone and quetiapine: Do these atypical antipsychotics have a protective effect for SARS-CoV-2?Schizophrenia research · 2022Article
- Incidence and outcomes of COVID-19 first wave pandemic in a French nursing home with residents suffering from severe mental illnesses.Psychiatry research · 2022Article
- Hydroxyzine Use and Mortality in Patients Hospitalized for COVID-19: A Multicenter Observational Study.Journal of clinical medicine · 2021Article
- Psychotropics and COVID-19: An analysis of safety and prophylaxis.L'Encephale · 2021Article
- Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS-CoV-2 infection?Journal of clinical pharmacy and therapeutics · 2021Review
- Challenges in Prescribing Clozapine in the Era of COVID-19: A Review Focused on Immunological Implications.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021Review
- An analysis of the possible protective effect of antipsychotics for SARS-CoV-2 in patients under treatment for severe mental illnesses.Schizophrenia research · 2021Article
- COVID-19 Pandemic: What about the Safety of Anti-Coronavirus Nanoparticles?Nanomaterials (Basel, Switzerland) · 2021Review
- Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants.Scientific reports · 2021Article
- Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19?Medical hypotheses · 2021Article
- Functional and druggability analysis of the SARS-CoV-2 proteome.European journal of pharmacology · 2021Article
- Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises.Computational and structural biotechnology journal · 2021Review
- Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities.Advances and applications in bioinformatics and chemistry : AABC · 2021Article
- The Vagal Autonomic Pathway of COVID-19 at the Crossroad of Alzheimer's Disease and Aging: A Review of Knowledge.Journal of Alzheimer's disease reports · 2020Review
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.